Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Trial ID NCT02606123

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.	Clin Cancer Res	2016	0.87
2	Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.	Prostate Cancer Prostatic Dis	2016	0.83
3	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer.	Clin Med Insights Oncol	2016	0.83
4	New drugs in prostate cancer.	Prostate Int	2016	0.80
5	EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor.	ACS Chem Biol	2016	0.80
6	Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.	J Biol Chem	2016	0.77
7	An imaging agent to detect androgen receptor and its active splice variants in prostate cancer.	JCI Insight	2016	0.77
8	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.	Curr Urol Rep	2016	0.77
9	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.	Curr Opin Endocrinol Diabetes Obes	2016	0.76
10	A sting in the tail: the N-terminal domain of the androgen receptor as a drug target.	Asian J Androl	2016	0.76
11	Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.	Exp Hematol Oncol	2016	0.75